Core Insights - IMUNON, Inc. is in Phase 3 development of its DNA-mediated immunotherapy, IMNN-001, targeting advanced ovarian cancer, showcasing significant potential as highlighted in a recent public webcast featuring key opinion leaders and clinical data [1][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [3] - The company is advancing its non-viral DNA technology through two main modalities: TheraPlas for gene-based delivery of cytokines in solid tumors, and PlaCCine for gene delivery of viral antigens [3] Clinical Programs - The lead clinical program, IMNN-001, is a DNA-based immunotherapy for localized treatment of advanced ovarian cancer, having completed multiple trials including a Phase 2 trial (OVATION 2) and currently conducting a Phase 3 trial (OVATION 3) [4] - IMNN-001 functions by instructing the body to produce cancer-fighting molecules at the tumor site, including interleukin-12 and interferon gamma [4] - The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101, and aims to advance its technological capabilities through partnerships [4]

Core Viewpoint - IMUNON, Inc. announced a 15% stock dividend, reflecting the company's confidence in its Phase 3 clinical study and long-term growth potential, while also demonstrating dedication to its shareholders [1][3]. Group 1: Stock Dividend Details - The stock dividend program will distribute approximately 448,000 additional shares of IMUNON common stock for each share held, payable to holders of record as of August 7, 2025, with distribution expected on August 21, 2025 [2]. - Stockholders will not need to take any action to receive the dividend, as additional shares will be credited to their accounts [2]. Group 2: Company Strategy and Clinical Programs - The stock dividend is a way for the company to share its recent clinical progress and optimism with shareholders, emphasizing its commitment to creating value while advancing its innovative pipeline of therapies [3]. - IMUNON is focused on developing transformative treatments, including its lead program IMNN-001 for advanced ovarian cancer, which has shown promising Phase 2 clinical data and is currently in a Phase 3 pivotal trial [3][5]. Group 3: Company Overview - IMUNON is a clinical-stage biotechnology company that develops innovative treatments utilizing non-viral DNA technology, with a focus on solid tumors and immunological responses [4]. - The lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, instructing the body to produce cancer-fighting molecules at the tumor site [5].